Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.
Radiotherapy combined with chemotherapy is the treatment of choice for glioblastoma and locally advanced lung cancer, but radioresistance of these two types of cancer remains a significant therapeutic hindrance. To identify molecular target(s) for radiosensitization, we screened a small interfering RNA (siRNA) library targeting all protein kinases and E3 ubiquitin ligases in the human genome and identified tumor necrosis factor receptor-associated factor 2 (TRAF2). Silencing of TRAF2 using siRNA caused a significant growth suppression of glioblastoma U251 cells and moderately sensitized these radioresistant cells to radiation. Overexpression of a really interesting new gene (RING)-deleted dominant-negative TRAF2 mutant also conferred radiosensitivity, whereas overexpression of wild-type (WT) TRAF2 significantly protected cells from radiation-induced killing. Likewise, siRNA silencing of TRAF2 in radioresistant lung cancer H1299 cells caused growth suppression and radiosensitization, whereas overexpression of WT TRAF2 enhanced radioresistance in a RING ligase-dependent manner. Moreover, siRNA silencing of TRAF2 in UM-SCC-1 head and neck cancer cells also conferred radiosensitization. Further support for the role of TRAF2 in cancer comes from the observations that TRAF2 is overexpressed in both lung adenocarcinoma tissues and multiple lung cancer cell lines. Importantly, TRAF2 expression was very low in normal bronchial epithelial NL20 cells, and TRAF2 silencing had a minimal effect on NL20 growth and radiation sensitivity. Mechanistically, TRAF2 silencing blocks the activation of the nuclear factor-kappaB signaling pathway and down-regulates several G(2)-M cell cycle control proteins, resulting in enhanced G(2)-M arrest, growth suppression, and radiosensitization. Our studies suggest that TRAF2 is an attractive drug target for anticancer therapy and radiosensitization.
Zheng
Min
M
Division of Radiation and Cancer Biology, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109-5637, USA.
Morgan-Lappe
Susan E
SE
Yang
Jie
J
Bockbrader
Katrina M
KM
Pamarthy
Deepika
D
Thomas
Dafydd
D
Fesik
Stephen W
SW
Sun
Yi
Y
D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000528:radiation effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy*; D018797:Cell Cycle Proteins / Q000378:metabolism; D002455:Cell Division / Q000235:genetics / Q000528:radiation effects; D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D016195:G2 Phase / Q000235:genetics / Q000528:radiation effects; D020868:Gene Silencing; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy / Q000628:therapy*; D051379:Mice; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism; D028861:Nuclear Pore Complex Proteins / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics*; D016601:RNA-Binding Proteins / Q000378:metabolism; D011836:Radiation Tolerance / Q000235:genetics; D047992:TNF Receptor-Associated Factor 2 / Q000235:genetics*
C119724:AGFG1 protein, human; D018797:Cell Cycle Proteins; D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; C000606205:Nfkbia protein, mouse; D028861:Nuclear Pore Complex Proteins; D034741:RNA, Small Interfering; D016601:RNA-Binding Proteins; D047992:TNF Receptor-Associated Factor 2; D000072000:NF-KappaB Inhibitor alpha
Assay Drug Dev Technol. 2003 Feb;1(1 Pt 2):175-80
15090144
FASEB J. 2005 Apr;19(6):620-2
15670977
Oncogene. 2004 Sep 16;23(42):7047-52
15258565
Cell. 1995 Dec 29;83(7):1243-52
8548810
J Cell Sci. 2002 Feb 15;115(Pt 4):679-88
11865024
Am J Pathol. 2003 Apr;162(4):1151-62
12651607
J Biomol Screen. 1999;4(2):67-73
10838414
Cell. 1996 Jan 26;84(2):299-308
8565075
Oncogene. 2005 Nov 10;24(49):7381-8
16044155
J Immunol. 1999 Apr 15;162(8):4447-54
10201981
Genes Dev. 1998 Sep 15;12(18):2821-30
9744859
Oncogene. 2008 May 22;27(23):3244-55
18084327
Genes Dev. 1993 Nov;7(11):2064-70
8224838
J Clin Invest. 1991 Aug;88(2):691-5
1864978
Drug Resist Updat. 2007 Aug-Oct;10(4-5):162-81
17669681
Am J Respir Crit Care Med. 2005 Sep 1;172(5):523-9
15961694
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):927-31
14967452
Cancer Biol Ther. 2003 Nov-Dec;2(6):623-9
14688465
Immunity. 1997 Nov;7(5):715-25
9390694
Int J Cancer. 2001 Oct 1;94(1):1-5
11668471
Immunity. 1997 Nov;7(5):703-13
9390693
Cancer Res. 2001 May 15;61(10):3986-97
11358816
Sci STKE. 2005 Feb 22;2005(272):pe7
15728425
Mol Biol Cell. 2002 Jun;13(6):1929-39
12058060
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5742-6
8516323
Cancer Res. 2001 Nov 15;61(22):8211-7
11719452
EMBO J. 2004 Jan 28;23(2):322-32
14713952
Cancer Metastasis Rev. 2004 Aug-Dec;23(3-4):209-25
15197324
Radiat Res. 2002 Mar;157(3):322-30
11839095
Oncogene. 2001 Apr 26;20(18):2243-53
11402319
Nat Med. 2002 Aug;8(8):816-24
12118244
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14453-8
9826721
Nat Rev Cancer. 2007 Nov;7(11):861-9
17943134
J Biochem Mol Biol. 2002 Jan 31;35(1):61-6
16248971
Oncogene. 2007 Apr 26;26(19):2707-16
17057733
Mol Biol Cell. 2002 Oct;13(10):3431-40
12388747
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Br J Cancer. 2008 Feb 12;98(3):523-8
18231106
Nature. 2006 May 25;441(7092):431-6
16724054
Nature. 2001 Aug 23;412(6849):822-6
11518967
Cancer Res. 2007 May 1;67(9):4390-8
17483353
Genes Dev. 2001 Jun 1;15(11):1311-33
11390353
Oncogene. 2001 Oct 1;20(44):6482-91
11607847
Mol Cancer Ther. 2006 Mar;5(3):637-44
16546978
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9
11707590
Science. 1998 Sep 11;281(5383):1680-3
9733516
Acta Neurochir Suppl. 2003;88:37-43
14531559
Neoplasia. 2006 Aug;8(8):645-54
16925947
Semin Oncol. 2004 Oct;31(5):635-44
15497116